A call on Sanuwave's third-quarter results starts at 8:30 a.m. ET; a replay runs through Nov. 25.

Sanuwave Health (NASDAQ: SNWV) will host a Q3 2026 earnings call on Nov. 11, 2026, at 8:30 AM ET. A replay will be available until Nov. 25. The company focuses on wound care products and regenerative medicine technologies. Forward-looking statements include typical risks and uncertainties.

Original reporting
Published Nov 6, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SNWV
Neutral
medium confidence
Mentioned
$SNWV
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SNWVNeutralMed
01

Why it matters

The main tradable element is event timing for SNWV’s earnings communication; the article itself does not disclose any new financial datapoint.

02

Market read

Provides the exact call time and replay availability for SNWV’s Q3 results, which can drive pre-call positioning and post-call repricing once results are released.

03

What to watch

Traders should watch for whether the company’s Q3 materials include changes in capital resources, regulatory posture, or production expectations, since those are highlighted as key risk areas in the boilerplate.

Relevance 4/10Novelty 4/10Timing: Ahead of the Nov. 11, 8:30 a.m. ET Q3 2026 results call, with replay available through Nov. 25.

Background

The company announces a live conference call to present Q3 2026 financial results, plus dial-in and webcast access, and a replay window.

Company-level read

Ticker impact

$SNWVNeutralMedium confidence
Context

Sanuwave (SNWV) will host a live call at 8:30 a.m. ET on Nov. 11 to present its Q3 2026 financial results, with a replay through Nov. 25.

Expected impact

Likely volatility around the call as the market prices the upcoming Q3 results and any management outlook discussed.

Evidence & confidence

The article provides timing and format for the Q3 results presentation but does not include the actual financial numbers or guidance, so direction depends on the forthcoming earnings content.

Market effects

Limited sector read-through because the piece contains no clinical, regulatory, or product milestone details.

Minimal, as it is a single-company investor-relations event.

Low, since it is not tied to global macro or cross-border corporate actions.

Counterpoint

Because the release contains no earnings numbers or guidance, it may not justify positioning beyond event-risk management until the actual Q3 results are published.

Key entities

  • Sanuwave Health, Inc.

    NASDAQ-listed wound care products provider scheduled to present Q3 2026 financial results on Nov. 11 at 8:30 a.m. ET.

Related articles

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMed

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.